Antimicrobials · Clostridioides difficile infection
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Fidaxomicin is the first-line treatment for Clostridioides difficile infection (CDI) according to current IDSA guidelines.
The mechanism of action is inhibition of bacterial RNA polymerase by binding the switch region of the RNAP clamp, blocking open-complex formation and transcription initiation.
Fidaxomicin is a narrow-spectrum macrocyclic antibiotic that exhibits minimal systemic absorption.
It is preferred over oral vancomycin due to a significantly lower rate of recurrent CDI.
The drug exerts a bactericidal effect specifically against Clostridioides difficile while sparing the normal gut microbiota.
Fidaxomicin is given orally as a 200 mg tablet twice daily for 10 days or as granules for oral suspension (weight-based dosing in children) and is not effective for systemic infections.
It is considered the drug of choice for patients at high risk for recurrence, including the elderly and those with comorbidities.
Vignette unlocked
A 72-year-old female is hospitalized for a hip fracture and develops watery diarrhea and abdominal cramping on day 5 of antibiotic therapy. Stool studies are positive for Clostridioides difficile toxin. The patient has a history of recurrent CDI episodes in the past year. Her vitals are stable, and she is currently afebrile.
Which of the following is the most appropriate first-line treatment to reduce the risk of further recurrence in this patient?
Fidaxomicin
Fidaxomicin is the preferred first-line agent for CDI, particularly in patients at high risk for recurrence, because it preserves the gut microbiome and has superior efficacy in preventing relapse compared to vancomycin.
Full handout
High yield triage
Classification
Macrocyclic antibiotic; bactericidal agent.
Indications
Clostridioides difficile infection (CDI).
Mechanism of Action
Inhibits RNA polymerase by binding the switch region of the enzyme clamp.
Side Effects
Nausea, vomiting, abdominal pain.
Contraindications / Monitoring
Hypersensitivity; no routine monitoring required.
Full handout
Mechanism of Action
Bind site is the switch region of the RNA polymerase clamp, distinct from the rifamycin site, so there is no cross-resistance with rifampin. This inhibits transcription, leading to bacterial cell death. It is highly selective for Clostridioides difficile, sparing the commensal gut flora.
Unique Properties
Unlike oral vancomycin, fidaxomicin has a narrow spectrum of activity. It exhibits a significant post-antibiotic effect, which helps prevent the recurrence of CDI.
Indications
It is the first-line treatment for Clostridioides difficile infection (CDI), FDA-approved for adults and pediatric patients 6 months of age and older. It is preferred over vancomycin to reduce the risk of recurrent CDI.
Pharmacokinetics
Fidaxomicin has minimal systemic absorption, ensuring high concentrations remain in the gastrointestinal tract. No dose adjustment is recommended based on renal function; hepatic impairment has not been studied, but elimination is not expected to be significantly affected.
Side Effects & Adverse Events
Common adverse effects include nausea, vomiting, and abdominal pain. Hypersensitivity reactions including angioedema and dyspnea are rare but serious. It is generally well-tolerated compared to other systemic antibiotics.
Contraindications
Hypersensitivity to fidaxomicin or any of its components is an absolute contraindication. There are no specific drug-drug interactions of clinical significance due to its lack of systemic absorption.
Monitoring
No routine laboratory monitoring is required. Clinicians should monitor for the resolution of diarrhea and signs of toxic megacolon if the patient fails to improve.
Clinical Pearls
On boards, choose fidaxomicin to reduce the risk of recurrent CDI. It is the preferred agent for patients with a high risk of recurrence, distinguishing it from the older standard of oral vancomycin.